COVID-19 and acute kidney injury in German hospitals

2 2020

21

COVID-19 and AKI in Germany 3 4 5 6 7 8 Victor Walendy¹, Matthias Girndt¹, Daniel Greinert¹ 9 10 11 12 Department of Internal Medicine II 13 Medical Faculty of the 14 Martin-Luther-University Halle-Wittenberg 15 Ernst-Grube-Straße 40 16 D-06120 Halle (Saale) 17 Germany 18 19 Corresponding author: 20 Victor.walendy@uk-halle.de

Abstract

Introduction

The SARS-CoV-2 pandemic is a major challenge for patients, healthcare professionals, and populations worldwide. While initial reporting focused mainly on lung involvement, the ongoing pandemic showed that multiple organs can be involved, and prognosis is largely influenced by multi-organ involvement. Our aim was to obtain nationwide retrospective

population-based data on hospitalizations with COVID-19 and AKI.

Materials & Methods

We performed a query of G-DRG data for the year 2020 via the Institute for the hospital remuneration system (Institut für das Entgeltsystem im Krankenhaus GmbH, InEK) data portal and therefore included hospitalizations with a secondary diagnosis of RT-PCR proven COVID-19 infection, aged over 15 years. We included hospitalizations with acute kidney injury (AKI) stages 1 to 3. Age-specific and age-standardized hospitalization and in-hospital mortality rates (ASR) per 100.000 person years were calculated, with the German population of 2011 as the standard.

Results

In 2020, there were 16.776.845 hospitalizations in German hospitals. We detected 154.170 hospitalizations with RT-PCR proven COVID-19 diagnosis. The age-standardized hospitalization rate for COVID-19 in Germany was 232,8 per 100.000 person years (95% CI 213,6-233,9). The highest proportion of hospitalizations associated with COVID-19 were in the age group over 80 years. AKI was diagnosed in 16.773 (10,9%) of the hospitalizations

with COVID-19. The relative risk of AKI for males was 1,49 (95%CI 1,44-1,53) compared to females. Renal replacement therapy (RRT) was performed in 3.443 hospitalizations, 20,5% of the hospitalizations with AKI. For all hospitalizations with COVID-19, the in-hospital mortality amounted to 19,7% (n= 30.300). The relative risk for in-hospital mortality was 3,87 (95%CI 3,80-3,94) when AKI occurred. The age-standardized hospitalization rates for COVID-19 took a bimodal course during the observation period. The first peak occurred in April (ASR 23,95 per 100.000 person years (95%CI 23,58-24,33)), hospitalizations peaked again in November 2020 (72,82 per 100.000 person years (95%CI 72,17-73,48)). The standardized rate ratios (SRR) for AKI and AKI-related mortality with the overall ASR for COVID-19 hospitalizations in the denominator, actually decreased throughout the observation period and remained lower in autumn than they were in spring. In contrast to all COVID-19 hospitalizations, the SRR for overall mortality in COVID-19 hospitalizations diverged from hospitalizations with AKI in autumn 2020.

Discussion

 Our study for the first time provides nationwide data on COVID-19 related hospitalizations and acute kidney injury in Germany in 2020. AKI was a frequent complication and associated with high mortality. We observed a less pronounced increase in the ASR for AKI-related mortality during autumn 2020. The proportion of AKI-related mortality in comparison to the overall mortality decreased throughout the course of the pandemic.

Introduction

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

The SARS-CoV-2 pandemic is a major challenge for patients, healthcare professionals, and populations worldwide. While initial reporting focused mainly on lung involvement, the ongoing pandemic showed that multiple organs can be involved, and prognosis is largely influenced by multi-organ involvement. According to published data, the kidney is the second most involved organ. In a study from the New York City area, 22,2% of hospitalized patients showed acute kidney injury (AKI)(1). A meta-analysis (2) confirmed the high AKI rate among COVID-19 patients. In contrast to this, there is also data with lower incidence of AKI(3.4) especially early analysis from Wuhan, China did not show high incidence rates of AKI (3-5). However, different definitions of AKI complicate comparability. In critically ill patients with COVID-19 as many as 55 to 90% experienced AKI (6-8), of whom 21 to 37% required renal replacement therapy (RRT) (6,8,9). The mortality rates of patients with acute kidney injury are significantly higher than in patients without AKI. In a study by Chan et al. (9), the in-hospital mortality was 50% among patients with, versus 8% among those without AKI. An analysis by Fisher et al. (8) found similar mortality rates (52% vs. 19.6%). In addition, the length of stay (LOS) was markedly prolonged when AKI occurred (9,10). The German healthcare system offers comprehensive insurance coverage and, by international comparison, a high level of healthcare services. Throughout the COVID-19 pandemic there were no apparent acute care resource limitations, and the hospital capacities were at their limit but not overwhelmed. Nationwide unselected data, especially covering a longer time interval is not available. There is one observational study, which included 10.021 hospitalizations (11). The data from this study was obtained from one

German health insurance company and covered a short period of time (from February 26

until April 19, 2020). In this study, AKI was not addressed.

Our aim was to obtain nationwide retrospective population-based data on hospitalizations

with COVID-19 and AKI. Our query covered data from the year 2020 and contains, to our

knowledge, the most comprehensive data regarding patients with COVID-19 and AKI in

Germany.

Materials & Methods

Data Source

In accordance with the German Hospital Financing Act (KHG), a universal, performance-based remuneration system was introduced for general hospital services. The basis for this is the German-Diagnosis Related Groups system (G-DRG system), whereby each inpatient case of treatment is remunerated by means of a corresponding DRG rate. All hospitals submit their hospitalization data to the Institute for the hospital remuneration system (Institut für das Entgeltsystem im Krankenhaus GmbH, InEK). After submission, a plausibility control of the data is carried out by InEK. The submission of hospitalization data is mandatory for reimbursement of hospital stays. This leads to a strong incentive for hospitals to supply complete data, covering virtually every hospital in Germany. The transferred data include information on age, sex, discharge type, primary and secondary ICD-10-GM(12) coded diagnosis (International Classification of Diseases, 10th Edition, German Modification Version 2020) and performed operations and procedures (Operationen- und Prozedurenschlüssel Version 2020, OPS) (13). We performed a query of G-DRG data for the year 2020 via the InEK data portal (https://datenbrowser.inek.org/). The InEK data are

available in aggregated form, so that differentiation by federal state is not possible. Differentiation by age can only be made in the predefined age groups and differentiation by gender only indirectly. The G-DRG data provided by InEK have been described in detail elsewhere (14).

Cohort selection

We included hospitalizations with a secondary diagnosis of RT-PCR proven COVID-19 infection (ICD-10-GM: U07.1), aged over 15 years. We excluded hospitalizations 15.525 (9,1%) with hospital transfer and unknown discharge status from our analysis. We identified hospitalizations with acute kidney injury by their corresponding ICD-10-GM codes (S1 Table). We included hospitalizations with acute kidney injury stages 1 to 3 (AKIN 1 to 3) (15). We further searched for OPS codes indicating hemodialysis and mechanical ventilation (S1 Table). The survival status at the end of each hospitalization was obtained by discharge type. The observation period was from 01.02.2020 throughout 31.12.2020.

Statistical analysis

We calculated crude, age-specific and age-standardized hospitalization rates (ASR) per 100.000 person years and the respective 95% confidence intervals (95% CI). We used the standard population of Germany in 2011 (16), provided by the Federal Bureau of Statistics (DESTATIS), for direct age-standardization (S2 Table). We further calculated standardized rate ratios (SRR), with their respective confidence intervals. Continuous variables are reported with standard deviation (SD). Categorical data is reported in absolute numbers and percentages. We used the ICD-10 version of the Elixhauser comorbidity index (ECI) to assess comorbidities (17). We excluded acute kidney injury as a comorbidity. All data analysis was

- carried out using R (Version 3.6.3) (18), for direct age-standardization the epitools package
- 131 (19) was used, contingency tables were evaluated using the epiR package(20).

Results General characteristics and age-standardized rates In 2020, there were 16.776.845 hospitalizations in German hospitals. We detected 154.170 hospitalizations with RT-PCR proven COVID-19 diagnosis throughout the observation period. There were 79.781 (51,8%) male and 74.382 (48,2%) female patients hospitalized, respectively (Table 1). In 29.329 (19,0%) of the COVID-19 associated hospitalizations the treatment included an intensive care unit (ICU) stay. The age-standardized hospitalization rate for COVID-19 in Germany was 232,8 per 100.000 person years (95% CI 213,6-233,9) in 2020. Most hospitalizations (1394,1 per 100.000 person years) occurred in the age group of 80 years and older (Fig 1).

	AKI		ICU		Overall	Overall		
N	16.	773	29.	329	154	154.170		
Gender	%	n	%	n	%	n		
male	61,5 (10.308)		62,6 (1	18.361)	51,8 (7	51,8 (79.781)		
female	38,5 (6.463)		37,4 (1	10.965)	48,2 (7	48,2 (74.382)		
Age group (years)	% n		% n		%	n		
16-17	0,0%	1	0,1%	38	0,3%	472		
18-29	0,4%	70	1,7%	493	4,0%	6143		
30-39	0,7%	112	2,8%	829	5,3%	8185		
40-49	1,9% 326		5,8%	1704	7,5%	11601		
50-54	2,6% 443		5,8%	1688	6,2%	9537		
55-59	4,5% 754		7,9% 2312		7,5%	11602		
60-64	6,8% 1134		9,6% 2818		7,7%	11858		
65-74	20,3%	3408	21,8%	6398	16,5%	25418		
75-79	17,0%	2851	14,6% 4282		11,7%	18045		
80+	45,8%	7674	29,9%	8767	33,3%	51309		
length of stay (days, SD)	18,4	(16,9)	18,3 (16,7)		11,3 (11,9)			
Elixhauser comorbidity index (%, n)	%	n	%	n	%	n		
0	60 (10.041)		65 (18	8.918)	65 (99.783)			
1–4	24 (4.029)		25 (7	.186)	25 (39.117)			
>=5	16 (2	.703)	10 (3	.225)	10 (1	10 (15.270)		
mean (SD)	2,0	(3,8)	1,6	(3,8)	1,2	(3,1)		

Table 1. General characteristics of COVID-19 hospitalizations in Germany 2020.

ICU: intensive care unit - hospitalizations with intensive care treatment during the hospital stay, AKI: acute kidney injury - hospitalizations with acute kidney injury (Acute kidney injury network Stage 1-3), SD: standard deviation

156 Fig 1. Age-specific rates of COVID-19 hospitalizations in Germany 2020 (per 100.000 person

157 years)

Hospital incidence of acute kidney injury

Acute kidney injury, including AKI Stages 1-3, was diagnosed in 16.773 (10,9%) of the hospitalized cases with COVID-19. The ASR for AKI was 25.8 (95%CI 25.4-26.2) per 100.000 person years (Table 2). While men and women were equally distributed among those hospitalized for COVID-19, men were more affected by AKI than women. The relative risk of AKI for males was 1,49 (95%CI 1,44-1,53) compared to females hospitalized with COVID-19 (52 Table). We determined 10.310 (61,5%) male and 6.463 (38,5%) female hospitalizations with acute kidney injury, respectively (Table 1). The proportion of the severity of acute kidney injury was distributed as follows: 32,0% (n= 5.407) developed AKI Stage 1, AKI Stage 2 was present in 27,4 % (n= 4.625) and in 40,6% (n= 6.842) AKI Stage 3 was coded. There were 101 hospitalizations with more than one code for AKI. When acute kidney injury was present during hospital stay, 8.374 (49,9 %) needed intensive care. Furthermore, mechanical ventilation was required in 7.050 (42,0 %) hospitalizations with acute kidney injury (Table 2). The relative risk for hospitalizations with AKI to be treated in an intensive care unit was 3,27 (95%CI 3,21-3,34) (Table 3).

-	-
	,
	_

	AKI		ICU		Overall		
	n	%	n	%	n	%	
Overall	16.773 (10,9%)		29.329	(19,0%)	154.170 (-)		
Renal replacement therapy	3.443 (20,5%)		3.046 (10)	,4%)	-		
males	2.635 76,5%		2.335	2.335 76,7%		-	
females	808	23,5%	711	23,3%	-	-	
In-hospital mortality	9.717	(57,9%)	12.322	(40,6%)	30.300 (19,7%)		
males	6.283	64,7%	7.990	64,8%	17.635	58,2%	
females	3.434	35,3%	4.330	35,2%	12.665	41,8%	
AKI Stages							
1	5.407	32,0%	1.865	20,3%	-		
2	4.625	27,4%	2.011	21,8%	-		
3	6.842	40,6%	5.333	57,9%	-		
Chronic kidney disease	5.524	(32,9%)	5.365	(18,3%)	23.380 (15,2%)		
G3	3.638	21,7%	3.225 11,0%		15.270	9,9%	
G4	1.490	8,9%	1.084	3,7%	4.535	2,9%	
G5	396	2,4%	1.056	3,6%	3.575	2,3%	
Mechanical ventilation	7.050	(42,0%)	17.144 (58,5%)		-		
males	5.052	71,6%	11.508	67,1%	-		
females	1.998	28,3%	5.634	32,9%	-		
Age-standardized rate (per 100.000 PYRs, 95% CI)	25,8 (25,4-26,2)		44,0 (43	3,5-44,5)	232.8 (213.6-233.9)		

174 Table 2: Results COVID-19 hospitalizations in Germany 2020,

ICU: intensive care unit - hospitalizations with intensive care treatment during the hospital stay, AKI: acute kidney injury - hospitalizations with acute kidney injury (acute kidney injury network, Stage 1-3), 95%CI: 95 % confidence interval, PYRs: person years

		ICU	N	Non-ICU			
	N	%	N	%	n		
AKI	8.374	8.374 49,9		50,1	16.773		
Non-AKI	20.955	20.955 15,3%		84,7%	137.397		
Overall	29.329	19,0%	124.841	81,0%	154.170		
	De	Deceased %		Alive			
	N			%	N		
AKI	9.717	57,9%	7.056	42,1%	16.773		
Non-AKI	20.583	15,0%	116.814	85,0%	137.397		
Overall	30.300	30.300 19,7%		80,3%	154.170		

Table 3: Contingency table for AKI and risk of ICU admission or in-hospital mortality, ICU: intensive care unit - hospitalizations with intensive care treatment during the hospital stay, AKI: acute kidney injury - hospitalizations with acute kidney injury (acute kidney injury network, Stage 1-3)

Renal replacement therapy

When acute kidney injury was present, renal replacement therapy (RRT) was performed in 3.443 hospitalizations, 20,5% of hospitalizations with AKI and 2,2% of all COVID-19 associated hospitalizations. Furthermore, when RRT was conducted, mechanical ventilation was needed in 2.380 (69,1%) cases. The modality of renal replacement therapy was intermittent RRT in 230 (6,7%), and continuous or prolongend intermittend RRT in 3.213 (93,3%) hospitalizations, respectively. In 828 (24,0%) hospitalizations more than one procedure code indicating RRT was present.

Chronic kidney disease (CKD Stages 3 to 5) was present in 23.380 (15.2%) hospitalizations with AKI. We observed 3.638 (21,7%) hospitalizations with AKI and CKD Stage G3, in 1.490 (8.9%) hospitalizations CKD G4 was prevalent and 396 (2,4%) had CKD G5, respectively.

In-hospital mortality

For all hospitalizations with COVID-19, the in-hospital mortality amounted to 19,7% (n= 30.300). Of these, 58,2% (n= 17.635) were men and 41,8% (n=12.665) were women (Table 2), respectively. The relative risk for in-hospital mortality for men amounted to 1,30 (95%CI 1,27-1,33) compared to women (S3 Table). The ASR for in-hospital mortality was 47,7 (95%CI 47,2-48,3) per 100.000 person years. Most deaths (511,2 per 100.000 person years) were observed in the age group over 80 years of age (Fig S1). When AKI was present, 9.717 died, accounting for 57,9% of deaths in this group (Table 2), the relative risk for in-hospital mortality was 3,87 (95%CI 3,80-3,94) when AKI occurred (Table 3). Moreover, when hemodialysis was performed, 2.891 died, which amounts to 61,4% of all hospitalizations with RRT.

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

15

observation period (Fig 2B) and remained lower in autumn than they were in spring. In

Comorbidities

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

The Elixhauser comorbidity index (ECI) varied among the different groups. The mean ECI for all COVID-19 associated hospitalizations was 1,2 (SD 3,1). For hospitalizations requiring intensive care the mean ECI was 1.6 (SD 3.8). When acute kidney injury was present the ECI increased to 2,0 (SD 3,8). In general, the four most common coded comorbidities were uncomplicated hypertension (35,3%), fluid and electrolyte disorders (20,6%), uncomplicated diabetes mellitus (13,3%) and cardiac arrhythmias (10,0%) (Fig 4). When acute kidney injury

or an ICU stay were coded, cardiac arrhythmias were relatively more prevalent compared to all hospitalizations with COVID-19 (Fig S2, S3).

Fig 4: Relative frequencies of comorbidities in COVID-19 hospitalizations in Germany 2020.

chf: congestive heart failure; carit: cardiac arrhythmias; valv: valvular disease; pcd: pulmonary circulation disorders; pvd: peripheral vascular disorders; hypunc: hypertension - uncomplicated; hypo: hypertension - complicated; para: paralysis; ond: other neurological disorders; cpd: chronic pulmonary disease; diabunc: diabetes -uncomplicated; diabc: diabetes- complicated; hypothy: hypothyroidism; ld: liver disease; pud: peptic ulcer disease- excluding bleeding; aids: AIDS/HIV; lymph: lymphoma; metacanc: metastatic cancer; solidtum: solid tumour: without metastasis; rheumd: rheumatoid arthritis/collaged vascular disease; coag: coagulopathy; obes: obesity; wloss: weight loss; fed: fluid and electrolyte disorders; blane: blood loss anaemia; dane: deficiency anaemia; alcohol: alcohol abuse; drug: drug abuse; psycho: psychoses; depre: depression;

Discussion

Our study for the first time provides nationwide data on COVID-19 hospitalizations and acute kidney injury in Germany in 2020. The key findings that emerge from our data are as follows. The highest proportion of hospitalizations associated with COVID-19 were in the age group over 80 years. The gender distribution was equal in COVID-19 related hospitalization, however, we observed that men more often developed acute kidney injury (RR 1,49 (95%CI 1,44-1,53)), needed ICU care and had a higher risk of in-hospital mortality (RR: 1,30 (95%CI 1,27-1,33)) than women. Our results thus exhibit a gender bias. This is consistent with a meta-analysis including 3.111.714 COVID-19 associated hospitalizations worldwide, which identified male sex as a risk factor for death and ICU-admission, despite the gender ratio being equal at the time of admission (21). Different underlying mechanisms - from hormonal, genetic to behavioral effects and risk factor prevalence — have been discussed in the literature (21,22).

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

New York state estimated that 53,6% of AKI patients needed invasive ventilation (10). This

higher numbers are likely reflective of more severe disease outcomes in patients with AKI.

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

to take care of relatives infected with COVID-19 or in quarantine. In contrast to the development discussed above, the ASR for AKI and AKI-related mortality had a disproportionately smaller increase and were already declining in December. The age distribution in our cohort was similar among all hospitalized patients, with a higher proportion of elderly patients in the second peak in October, November and December in comparison to February, March and April. Thus, differences in age distribution is not a good explanation for this finding (S4 Fig and S5). At this point, it must be said again that multiple factors could have influenced the ASR for AKI und AKI-related mortality. Apart from differences in the patient population or age distribution, changes in the treatment strategy e.g., the early use of drug therapies for patients with an increased risk of severe COVID-19 courses. The mean length of stay (LOS- discharged or dead) of all patients was 11,3 days and increased with AKI to 18,4 days. LOS varies in different studies, and - according to a systematic review by Rees et al. (31) - the median LOS was 14 days in China, compared with 5 (IQR 3-9) days outside of China. Similar figures were reported by Fisher et al. (8). This may be explained by many differences in criteria for admission and discharge between countries, and different timings in the course of the pandemic. Hospital capacities in Germany were not overwhelmed by the pandemic, and the pressure to discharge patients might have been lower. The most comprehensive analysis of German patients to date included 10.021 patients with a mean LOS of 14,3 days (32). This was longer than in our analysis, an explanation for the discrepancy could be timing of data collection. Karagiannidis et al.

collected their data at the beginning of the pandemic. Due to an increasing experience in

treating COVID-19 patients and new treatment options, the length of stay consequently declined.

The observed comorbidities varied between the different groups. Hypertension, diabetes mellitus, fluid and electrolyte disorders and cardiac arrhythmias were the most commonly coded comorbidities. This finding is plausible, as these are the most common comorbidities in patients with chronic kidney disease (33) and likewise known risk factors for hospitalization with COVID-19 (34). Cardiac arrhythmias became more prevalent in hospitalizations with AKI. Cardiac arrhythmias are a common finding in COVID-19, in particular with an increasing number of comorbidities (35).

Strengths and limitations

The major strength of this study is that we provide a nationwide population-based view on COVID-19 hospitalizations with acute kidney injury in Germany. We retrieved DRG-data covering virtually every hospital in Germany. In this study, we use routine hospitalization data, which is lacking clinical detail. This might lead to confounding that we could not adjust for. The InEK provides aggregated data due to data safety precautions, which is fully anonymized. It is, therefore, possible that this could lead to bias caused by readmission, though this possibility is limited, because of the severity of most cases and our efforts to exclude readmissions from the dataset. Another important fact to consider, when analyzing routine data, is the observation period. In our analysis the observation period ends in the midst of the second wave of the COVID-19 pandemic in Germany. This will lead to bias, as the outcome of these cases remains unknown, in particular for hospitalizations in the last month of the observation period.

Bibliography

- 396 1. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
- Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients
- 398 Hospitalized with COVID-19 in the New York City Area. JAMA Journal of the
- 399 American Medical Association. 2020;323(20):2052–9.
- 400 2. Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury
- in critically ill patients with COVID-19. Intensive Care Medicine [Internet].
- 402 2020;46(7):1339-48. Available from: https://doi.org/10.1007/s00134-020-06153-9
- 403 3. Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus disease 19 infection does not
- result in acute kidney injury: An analysis of 116 hospitalized patients from Wuhan,
- 405 China. American Journal of Nephrology. 2020;51(5):343–8.
- 406 4. Yang X, Jin Y, Li R, Zhang Z, Sun R, Chen D. Prevalence and impact of acute renal
- 407 impairment on COVID-19: A systematic review and meta-analysis. Critical Care.
- 408 2020;24(1):1–8.
- 409 5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
- 410 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
- 411 study. The Lancet [Internet]. 2020;395(10229):1054–62. Available from:
- 412 http://dx.doi.org/10.1016/S0140-6736(20)30566-3
- 413 6. Gupta S, Coca SG, Chan L, Melamed ML, Brenner SK, Hayek SS, et al. AKI treated with
- 414 renal replacement therapy in critically ill patients with COVID-19. Journal of the
- 415 American Society of Nephrology. 2021;32(1):161–76.
- 416 7. Thakkar J, Chand S, Aboodi MS, Gone AR, Alahiri E, Schecter DE, et al. Characteristics,
- 417 Outcomes and 60-Day Hospital Mortality of ICU Patients with COVID-19 and Acute
- 418 Kidney Injury. Kidney360. 2020;1(12):1339–44.

419 8. Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns TS, et al. AKI in Hospitalized 420 Patients with and without COVID-19: A Comparison Study. Journal of the American 421 Society of Nephrology [Internet]. 2020 Sep 1;31(9):2145 LP - 2157. Available from: 422 http://jasn.asnjournals.org/content/31/9/2145.abstract 423 9. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in hospitalized 424 patients with COVID-19. Journal of the American Society of Nephrology. 425 2021;32(1):151–60. 426 10. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury 427 in patients hospitalized with COVID-19. Kidney International. 2020;98(1):209-18. 428 11. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. 429 Case characteristics, resource use, and outcomes of 10â€^021 patients with COVID-19 430 admitted to 920 German hospitals: an observational study. The Lancet Respiratory 431 Medicine [Internet]. 2020 [cited 2021 Mar 11];8(9):853-62. Available from: 432 www.thelancet.com/respiratoryVol 433 12. Graubner B, Auhuber TC. ICD-10-GM Version 2020, Systematisches Verzeichnis, 434 Internationale statistische Klassifikation der Krankheiten und verwandter 435 Gesundheitsprobleme, 10. Revision, Stand: 20. September 2019 [Internet]. Köln: 436 Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) im Auftrag des 437 Bundesministeriums für Gesundheit (BMG) unter Beteiligung der Arbeitsgruppe ICD 438 des Kuratoriums für Fragen der Klassifikation im Gesundheitswesen (KKG); 2019. p. 439 September 2019. Available from: www.dimdi.de - Klassifikationen - Downloads -440 ICD-10-GM - Version 2021 441 13. Operationen- und Prozedurenschlüssel Internationale Klassifikation der Prozeduren

in der Medizin (OPS) Band 1: Systematisches Verzeichnis [Internet]. Bundesinstitut für

443 Arzneimittel und Medizinprodukte (BfArM) im Auftrag des Bundesministeriums für 444 Gesundheit (BMG) unter Beteiligung der Arbeitsgruppe ICD des Kuratoriums für 445 Fragen der Klassifikation im Gesundheitswesen (KKG); 2020. 740. Available from: 446 https://www.dimdi.de/dynamic/de/klassifikationen/icd/icd-10-gm/ 447 14. Busse R, Nimptsch U. COVID-19-Pandemie: Historisch niedrige Bettenauslastung. 448 Deutsches Aerzteblatt Online. 2021;118(10):10-3. 449 15. Levin A, Warnock DG, Mehta RL, Kellum JA, Shah S v., Molitoris BA, et al. Improving 450 Outcomes From Acute Kidney Injury: Report of an Initiative. American Journal of 451 Kidney Diseases. 2007;50(1):1-4. 452 16. Gesundheitsberichterstattung des Bundes [Internet]. 2021. Available from: 453 https://www.gbe-bund.de/gbe/pkg_isgbe5.prc_isgbe 454 17. Quan H, Sundararajan V, Halfon P, Fong A. Coding algorithms for defining 455 comorbidities in. Medical Care [Internet]. 2005;43(11). Available 456 http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Coding+Algorithms 457 +for+Defining+Comorbidities+in#1%5Cnhttp://scholar.google.com/scholar?hl=en&bt 458 nG=Search&g=intitle:Coding+algorithms+for+defining+comorbidities+in#1 459 18. Team RC. R: A Language and Environment for Statistical Computing [Internet]. 460 Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: www.r-461 project.org 462 19. Tomas J. Aragon. epitools: Epidemiology Tools. R package version 0.5-10.1. 2020. 463 20. Stevenson M, Sergeant E. epiR - Tools for the Analysis of Epidemiological Data. 2021. 464 21. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et

al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and

- 466 ITU admission. Nature Communications [Internet]. 2020;11(1):1–10. Available from:
- 467 http://dx.doi.org/10.1038/s41467-020-19741-6
- 468 22. Kelada M, Anto A, Dave K, Saleh SN. The Role of Sex in the Risk of Mortality From
- 469 COVID-19 Amongst Adult Patients: A Systematic Review. Cureus. 2020;12(8).
- 470 23. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
- 471 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients
- 472 Hospitalized With COVID-19 in the New York City Area. JAMA [Internet].
- 473 2020;323:2052–9. Available from: https://jamanetwork.com/
- 474 24. Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns TS, et al. AKI in Hospitalized
- Patients with and without COVID-19: A Comparison Study. Journal of the American
- 476 Society of Nephrology [Internet]. 2020 Sep 1;31(9):2145 LP 2157. Available from:
- http://jasn.asnjournals.org/content/31/9/2145.abstract
- 478 25. Richards-Belle A, Orzechowska I, Doidge J, Thomas K, Harrison DA, Koelewyn A, et al.
- 479 Critical care outcomes, for the first 200 patients with confirmed COVID-19, in
- 480 England, Wales and Northern Ireland: A report from the ICNARC Case Mix
- 481 Programme. Journal of the Intensive Care Society. 2020;0(0):1–10.
- 482 26. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
- 483 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A
- Review. JAMA Journal of the American Medical Association. 2020;324(8):782–93.
- 485 27. Sorci G, Faivre B, Morand S. Explaining among-country variation in COVID-19 case
- fatality rate. Scientific Reports. 2020 Dec 1;10(1).
- 487 28. Robert Koch Institut. Total overview of cases, deaths, and 7-day incidences reported
- per day to the RKI by state and county. [Internet]. 2021. Available from:
- 489 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges Coronavirus/Daten/Fallzahlen

490 Daten.html;jsessionid=4D411DFBB2E2575A9CD1F5504E7CE3BC.internet052?nn=134 491 90888 492 29. Asch DA, Sheils NE, Islam MN, Chen Y, Werner RM, Buresh J, et al. Variation in US 493 Hospital Mortality Rates for Patients Admitted with COVID-19 during the First 6 494 Months of the Pandemic. JAMA Internal Medicine. 2020;19104(4):471–8. 495 30. Dennis JM, McGovern AP, Vollmer SJ, Mateen BA. Improving COVID-19 critical care 496 mortality over time in England: A national cohort study, March to June 2020. 497 medRxiv. 2020;44(0). 498 31. Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, Pearson CAB, et al. COVID-499 19 length of hospital stay: A systematic review and data synthesis. medRxiv. 2020; 500 32. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. 501 Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 502 admitted to 920 German hospitals: an observational study. The Lancet Respiratory 503 medicine [Internet]. 2020 Sep [cited 2021 Mar 11];8(9):853-62. Available from: 504 www.thelancet.com/respiratoryVol 505 33. Reichel H, Zee J, Tu C, Young E, Pisoni RL, Stengel B, et al. Chronic kidney disease 506 progression and mortality risk profiles in Germany: Results from the Chronic Kidney 507 Disease Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation. 508 2020 May 1;35(5):803-10. 509 34. Ioannou GN, Locke E, Green P, Berry K, O'Hare AM, Shah JA, et al. Risk Factors for 510 Hospitalization, Mechanical Ventilation, or Death Among 102131 US Veterans With

SARS-CoV-2 Infection. JAMA network open. 2020;3(9):e2022310.

Sommilias EJ, Kochav S, Goldenthal I, Biviano A, Garan H, Goldbarg S, et al.
Worldwide Survey of COVID-19 Associated Arrhythmias. Circulation: Arrhythmia and Electrophysiology. 2021;(March):285–95.

518

519

520

521

522

523

524

525

526

527

528

529

530

531532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

30

S1 Table. List of ICD-10-GM and OPS Codes, version 2020

S2 Table. Contingency table AKI by sex

S3 Table. Contingency table in-hospital mortality by sex

December -	0.3	3.6	4.7	6.4	5.3	6.7	7.1	15.6	11.4	38.8	_
November -	0.3	3.7	5	7.1	5.9	7.2	7.4	16.8	11.9	34.7	_
October	0.4	4.9	6.3	8.9	7.1	7.9	8	16.9	11.3	28.4	_
September -	0.4	6.1	7.6	11.7	8.6	9.2	8.4	16.5	9.5	22.1	_
August	0.4	9.8	10.2	15.7	8.5	10.6	8.9	14.8	6.9	14.1	-
July –	0.6	9.3	11.1	14.7	9.4	8.5	7.6	14.5	6.5	17.8	
June –	0.7	8.7	10.6	11.4	9.3	8.1	7.2	12.9	8.1	22.9	-
May	0.2	5.3	6.6	7.9	6.5	8	7.4	16	11	31.3	
April –	0.2	3.1	4.5	6.8	5.9	7.8	8.1	16.3	12.5	34.7	
March	0.1	2.4	4.3	7.5	7.4	9	9.4	18.6	14.1	27.2	
February	0.8	3.8	4.9	4.6	4.2	7.6	8.7	21.7	13.7	30	_
	16.7>	46.50	600	N. K.	50.	45	00.	85.	150	&x	

December -	0	0.1	0.3	1.3	1.7	3.3	5.1	17.2	14.9	56.2	-
November –	0	0.4	0.5	1.5	2.2	3.9	6.3	19.9	17.6	47.8	_
October –	0	0.6	0.8	2.3	2.6	3.7	7.1	21.7	17.1	44	_
September –	0	0	0	3.2	4.7	4.7	9.3	20.7	17.5	39.9	-
August	0	2.6	3.3	4.6	3.9	8.6	7.9	29.6	12.5	27	- 50
July	0	1.6	2.3	6.2	3.9	1.6	7	27.1	16.3	34.1	40 30 20
June –	0	2.7	2	4.7	7.4	4.7	11.5	20.3	16.9	29.7	10
May	0	0.3	1	3.3	4.8	7.4	9.4	21.6	14.2	38.1	-
April –	0	0.5	1.1	2.2	3.1	5.4	7.6	21.6	17.1	41.3	-
March	0	0.4	0.8	2.4	3.9	7	8.3	22.5	19.8	35	-
February	0	0	0	1.8	0	3.6	7.1	28.6	17.9	41.1	_
	16.75	48.39	50.50	D. A.	\$0.5	35.59	60.00	55	150	& <u>`</u>	_

















